Evidence map›Paper›PMID 37046838›Full record

ArticleCancers2023

Disequilibrium between

Corentin Levacher, Mathieu Viennot, Aurélie Drouet, Ludivine Beaussire, Sophie Coutant, Jean-Christophe Théry, Stéphanie Baert-Desurmont, Marick Laé, Philippe Ruminy, Claude Houdayer

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Corentin LevacherUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique, 76000 Rouen, France.
Mathieu ViennotUniv Rouen Normandie, INSERM U1245, Centre Henri Becquerel, 76000 Rouen, France.
Aurélie DrouetUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique, 76000 Rouen, France.
Ludivine BeaussireUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique, 76000 Rouen, France.
Sophie CoutantUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique, 76000 Rouen, France.
Jean-Christophe ThéryUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique, 76000 Rouen, France.
Stéphanie Baert-DesurmontUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique and CHU Rouen, Department of Genetics, 76000 Rouen, France.ORCID 0000-0002-1172-4157
Marick LaéUniv Rouen Normandie, INSERM U1245, Centre Henri Becquerel, 76000 Rouen, France.ORCID 0000-0002-7448-9537
Philippe RuminyUniv Rouen Normandie, INSERM U1245, Centre Henri Becquerel, 76000 Rouen, France.
Claude HoudayerUniv Rouen Normandie, INSERM U1245, FHU-G4 Génomique and CHU Rouen, Department of Genetics, 76000 Rouen, France.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a frequent disease for which the discovery of markers that enable early detection or prognostic assessment remains challenging. Circular RNAs (circRNAs) are single-stranded structures in closed loops that are produced by backsplicing. CircRNA and messenger RNA (mRNA) are generated co-transcriptionally, and backsplicing and linear splicing compete against each other. As mRNAs are key players in tumorigenesis, we hypothesize that a disruption of the balance between circRNAs and mRNAs could promote breast cancer. Hence, we developed an assay for a simultaneous study of circRNAs and mRNAs, which we have called splice and expression analyses by exon ligation and high-throughput sequencing (SEALigHTS). Following SEALigHTS validation for

Indexed as

BRCA1/BRCA2breast cancercircular/messenger RNAs

Identifiers

PMID37046838
PMCPMC10093293
OpenAlexW4362668210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.